Breast cancer
CDK4/6 inhibitors for everyone? Treatment strategies in HR+ HER2- advanced breast cancer

Johanna (72 years old)

Johanna, 72 years old, was diagnosed with metastatic breast cancer 1 year ago, after she had been treated for early HR+ HER2- breast cancer 8 years ago.

Assessment summary:

  • Postmenopausal
  • Medical history:
    • HR+ HER2- breast cancer T2N0M0 8 years ago. Treated with breast conserving surgery, radiation therapy and letrozole for 5 years
    •  
    • Diagnosis metastatic disease 1 year ago (bones, liver). Biopsy of liver metastasis: breast cancer, NST, ER 90%, PgR 60%, HER2 IHC 1+, G2. Endocrine monotherapy with anastrozole was started
    • Tumour regression in control imaging
    • ECOG PS: 0
  • No family history of breast cancer
  • Most recent CT scan of chest and abdomen and bone scan:
    • Stable multiple bone metastases
    • Progression of 2 liver metastases
  • Haematology and biochemistry: all values normal
  • Germline BRCA-status: wild type
  • PIK3CA-status in the tumour: wild type

Which option would you choose for this patient?